Medicare Enrolled
Dr. Michael Nissenblatt, MD
Hematology & Oncology · East Brunswick, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Nissenblatt from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nissenblatt?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Nissenblatt
Dr. Michael Nissenblatt is a hematology & oncology specialist in East Brunswick, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Nissenblatt performed 89,497 Medicare services across 2,664 unique beneficiaries.
Between the years covered by Open Payments, Dr. Nissenblatt received a total of $17,857 from 21 pharmaceutical and/or device companies across 48 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Nissenblatt is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 12% volume in NJ
$17,857 industry payments
Medicare Practice Summary
Medicare Utilization ↗89,497
Medicare services
Top 12% in NJ for hematology & oncology
2,664
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,475 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
54,750 | $1 | $3 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
16,100 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 7,350 | $19 | $68 |
| Eflapegrastim injection, 0.1 mg An injection of eflapegrastim-xnst administered at a dose of 0.1 mg. |
2,904 | $26 | $98 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,472 | $8 | $31 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,100 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
843 | $107 | $421 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
570 | $12 | $48 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
483 | $69 | $300 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
451 | $8 | $23 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
416 | $6 | $14 |
| Injection, leucovorin calcium, per 50 mg | 287 | $3 | $11 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
278 | $26 | $101 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
241 | $118 | $463 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
223 | $152 | $587 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
208 | $56 | $228 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
205 | $67 | $249 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
203 | $1 | $6 |
| Anticoagulant management for warfarin Management of anticoagulant therapy for a patient taking warfarin. This service involves monitoring and adjusting the medication regimen. |
163 | $9 | $38 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
118 | $4 | $13 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
118 | $13 | $54 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
117 | $42 | $156 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
103 | $2 | $7 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
94 | $1 | $3 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
78 | $18 | $71 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 75 | $333 | $1,506 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
68 | $26 | $98 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
67 | $60 | $228 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
57 | $29 | $116 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
55 | $1 | $4 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
53 | $11 | $46 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
42 | $3 | $13 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
34 | $29 | $116 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
33 | $1 | $8 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
30 | $93 | $364 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
26 | $148 | $561 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
20 | $18 | $69 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
17 | $111 | $417 |
| New patient office visit, complex (60-74 min) | 16 | $175 | $725 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
16 | $47 | $188 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
13 | $34 | $104 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
62.3% high complexity
32.5% medium
5.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$17,857
Total received (2018-2024)
Avg $2,551/year across 7 years
Top 16% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
21
Companies
48
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$16,092 (90.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$941 (5.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$824 (4.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$76
2023
$193
2022
$704
2021
$172
2020
$806
2019
$12,984
2018
$2,923
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Regeneron Healthcare Solutions, Inc.
$63
Novartis Pharmaceuticals Corporation
$14
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$7,700
Bayer HealthCare Pharmaceuticals Inc.
$5,185
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,670
Daiichi Sankyo Inc.
$557
Athenex Pharmaceutical Division, LLC
$325
COMSORT, Inc
$250
Novocure GmbH
$200
GlaxoSmithKline, LLC.
$160
Karyopharm Therapeutics Inc.
$137
Exelixis Inc.
$128
Epizyme, Inc.,
$125
Amgen Inc.
$105
PFIZER INC.
$63
Regeneron Healthcare Solutions, Inc.
$63
Novartis Pharmaceuticals Corporation
$53
Janssen Biotech, Inc.
$45
Gilead Sciences, Inc.
$36
Verastem, Inc.
$15
EMD Serono, Inc.
$15
Merck Sharp & Dohme Corporation
$13
Seattle Genetics, Inc.
$11
Top 3 companies account for 87.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Bavencio · Blincyto · Cabometyx · Copiktra · DARZALEX · ENHERTU · Enhertu · GILOTRIF · IBRANCE · INJECTAFER · KEYTRUDA · LIBTAYO · LORBRENA · LUMAKRAS · LYNPARZA · Oral Paclitaxel · PLUVICTO · SIMPONI ARIA · SUTENT · TAGRISSO · TAZVERIK · Trodelvy · Vitrakvi · XALKORI · XPOVIO
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (90%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
Hematology & oncology specialists within 10 mi
189
Per 100K population
21.9
County median income
$109,028
Nearest hospital
ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL
4.0 mi
4.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Nissenblatt is a mixed practice specialist, with above-average Medicare volume (top 12% in NJ), with speaking/promotional industry engagement in the top 16% of NJ peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Nissenblatt experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Nissenblatt performed 54,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nissenblatt receive payments from pharmaceutical companies?
Yes. Dr. Nissenblatt received a total of $17,857 from 21 companies across 48 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nissenblatt's costs compare to other hematology & oncology specialists in East Brunswick?
Dr. Nissenblatt's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nissenblatt) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in East Brunswick
Browse hematology & oncology specialists in East Brunswick ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Bayer HealthCare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer HealthCare Pharmaceuticals Inc.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology